Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Petrillo, Marco ^a,b   Zannoni, Gian Franco ^a   Martinelli, Enrica ^a   Anchora, Luigi Pedone ^a   Ferrandina, Gabriella ^a   Tropeano, Giovanna ^a   Fagotti, Anna ^c   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; CISPLATIN; FLUOROURACIL; STAT PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR C MAF;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CELL POLARITY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MONOCYTE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; RADIATION DOSE; RADICAL HYSTERECTOMY; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CANCER; IMMUNOLOGY; IMMUNOPHENOTYPING; MACROPHAGE; MIDDLE AGED; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADULT; AGED; CELL POLARITY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MACROPHAGES; MIDDLE AGED; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84946222780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136654     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available: http://globocan.iarc.fr. Accessed 09/03/2013.
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30. doi: 10.3322/caac.21166 PMID: 23335087
3. McNeil C (1999) New standard of care for cervical cancer sets stage for next questions. J Natl Cancer Inst 91:500-501. PMID: 10088618
4. Keys HM, Bundy B, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 15:1154-1161.
5. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high risk cervical cancer. N Engl J Med 15:1137-1143.
6. Whitney CW, Sause W, Bundt WN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 17:1339-1348.
7. Rose PG, Bundy BN, Watkins, Thigpen JT, Deppe G, Maiman MA, et al. (1999) Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 15:1144-1153.
8. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606-1614. PMID: 10764420
9. Neoadjuvant Chemotherapy For Cervical Cancer Meta-Analysis Collaboration (2003) Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer 39:2470-2486. PMID: 14602133
10. Jurado M, Martinez-Monge R, Garcia-Foncillas J, Azinovic I, Aristu J, López-García G, et al. (1999) Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer. Gynecol Oncol 74:30-37. PMID: 10385548
11. Distefano M, Fagotti A, Ferrandina G, Fanfani F, Smaniotto D, D'Agostino G, et al. (2005) Preoperative chemoradiotherapy in locally advanced cervical cancer: long term outcome and complications. Gynecol Oncol 99:S166-70. PMID: 16150482
12. Ferrandina G, Margariti PA, Smaniotto D, Petrillo M, Salerno MG, Fagotti A, et al. (2010) Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol 119:404-10. doi: 10.1016/j.ygyno.2010.08.004 PMID: 20817228
13. Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, et al. (2012) Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 124:92-7. doi: 10.1016/j.ygyno.2011.09.034 PMID: 22014631
14. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, et al. (2010) Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 70:4840-9. doi: 10.1158/0008-5472.CAN-10-0269 PMID: 20501839
15. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000). M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 164:6166-73. PMID: 10843666
16. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18:349-55. doi: 10.1016/j.semcancer.2008.03.004 PMID: 18467122
17. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclearbphagocytes. Trends Immunol 23:549-55. PMID: 12401408
18. Cellini N, Smaniotto D, Scambia G, Luzi S, Balducci M, Ferrandina G, et al. (2008) Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study. Am J Clin Oncol. 31:280-284. doi: 10.1097/COC.0b013e31815aff03 PMID: 18525308
19. Zannoni GF, Vellone VG, Carbone A (2008) Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment. Int J Gynecol Pathol 27:274-81. doi: 10.1097/PGP.0b013e31815b1263 PMID: 18317212
20. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G (2013) Macrophagepolarisation: an immunohistochemical approach for identifying M1 and M2macrophages. PLoS One 8:e80908. doi: 10.1371/journal.pone.0080908 PMID: 24260507
21. Kaplan FL, Meier P (1958) Non parametric estimation from incomplete observations. Am J Stat Assoc 53:457-481.
22. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-70. PMID: 5910392
23. Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG (2013) Recruitment of monocytes/macrophages in different tumor microenvironments. Biochim Biophys Acta 1835:170-9. doi: 10.1016/j.bbcan.2012.12.007 PMID: 23287570
24. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al (2013) Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 73:2480-92. doi: 10.1158/0008-5472.CAN-12-3542 PMID: 23436796
25. deVos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, et al (2013) Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer. 133:2884-94. doi: 10.1002/ijc.28309 PMID: 23740735
26. Mazibrada J, Rittà M, Mondini M, De Andrea M, Azzimonti B, Borgogna C, et al (2008) Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol. 108:112-20. PMID: 17936343
27. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, et al (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumorally mphangiogenesis. Am J Pathol 161:947-56. PMID: 12213723
28. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-43. doi: 10.1056/NEJMoa1309748 PMID: 24552320
29. Allavena P, Germano G, Belgiovine C, D'Incalci M, Mantovani A (2013) Trabectedin: A drug from the sea that strikes tumor-associated macrophages. Oncoimmunology. 2:e24614. PMID: 23894721
30. Rigo A, Gottardi M, Zamò A, Mauri P, Bonifacio M, Krampera M, et al (2010) Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 9:273. doi: 10.1186/1476-4598-9-273 PMID: 20946648